Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...